Skip to main content
Fig. 5 | Fluids and Barriers of the CNS

Fig. 5

From: Serum-derived factors of breast cancer patients with brain metastases alter permeability of a human blood–brain barrier model

Fig. 5

Effects of recombinant BCA-1 and fractalkine treatment on BLECs. a BLECs were treated with indicated concentration of BCA-1, fractalkine or a combination of both for 24 h. Cell viability was assessed using MTT. b Messenger RNA expression of claudin-5 (CLDN5) and occludin (OCLN) in BLECS treated with indicated concentrations of BCA-1, fractalkine or a combination of both for 24 h. The target gene expression was normalized to endogenous control and shown as fold over control, which was arbitrarily set as 1 (control level marked in graph). Data are shown as mean ± SD. c Paracellular permeability for fluorescein of BLECs treated with indicated concentration of BCA-1, fractalkine (FKN) or a combination of both for 24 h. Data are shown as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page

Fluids and Barriers of the CNS

ISSN: 2045-8118